Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge

BioCryst Pharmaceuticals Inc. reported a significant earnings beat for the second quarter of 2025, with earnings per share (EPS) of $0.15 against a forecast of $0.01, marking a 1400% surprise. The company’s revenue reached $163.4 million, surpassing expectations of $149.82 million. Following the announcement, BioCryst’s stock surged 13.84% in pre-market trading, reflecting investor confidence in the company’s performance and future prospects. According to InvestingPro analysis, the company’s stock currently appears undervalued based on its Fair Value calculation, with analysts setting price targets ranging from $11 to $30.

Key Takeaways

• BioCryst achieved a 45% year-over-year revenue growth.
• The company paid down $125 million in debt, strengthening its financial position.
• Orlodayo continues to drive growth, with a significant portion of revenue from the U.S. market.
• The stock price increased by 13.84% in pre-market trading, indicating positive market sentiment.

Company Performance

BioCryst Pharmaceuticals demonstrated robust performance in Q2 2025, achieving significant revenue growth driven by its flagship product, Orlodayo. The company reported a non-GAAP operating profit of $57 million and a net income of $32.3 million. This performance underscores BioCryst’s strong position in the hereditary angioedema (HAE) market and its ability to expand its product offerings and market reach.

Financial Highlights

• Revenue: $163.4 million, up 45% year-over-year
• Earnings per share: $0.15, significantly exceeding the forecast of $0.01
• Non-GAAP operating expenses: $106.4 million
• Cash generated: $45 million in Q2
• Debt reduction: $125 million paid down

Earnings vs. Forecast

BioCryst’s Q2 2025 earnings per share of $0.15 far exceeded the forecast of $0.01, resulting in a 1400% earnings surprise. Revenue also surpassed expectations, with actual figures of $163.4 million compared to the forecast of $149.82 million, representing a 9.03% surprise. This marks a significant improvement over previous quarters, highlighting the company’s growth trajectory.

Market Reaction

BioCryst’s stock responded positively to the earnings announcement, with a 13.84% increase in pre-market trading. The stock’s last price was $9.05, up from the previous close of $7.95. This movement reflects investor optimism fueled by the company’s strong earnings performance and strategic debt reduction.

Outlook & Guidance

BioCryst projects full-year revenue between $580 million and $600 million, expecting to be in the upper half of this range. The company is focusing on consolidating its rare disease assets and exploring licensing and acquisition opportunities. Upcoming milestones include the Pediatric Orlodayo granules PDUFA date in December 2025. InvestingPro analysis reveals strong revenue growth with a 5-year CAGR of 56%, while analysts expect the company to achieve profitability this year. For deeper insights into BioCryst’s growth potential and comprehensive analysis, subscribers can access the detailed Pro Research Report, available exclusively on InvestingPro.

Executive Commentary

CEO John Stonehouse emphasized the company’s growth potential, stating, "We are on a path to $1,000,000,000 at peak and market leadership with Orlodayo." CFO Bob Urgeas highlighted BioCryst’s strong financial position, noting, "The market couldn’t be better for if you’re a buyer at the moment, and you don’t need to tap or raise more capital."

Risks and Challenges

• Potential competition from new HAE treatments could impact market share.
• Regulatory delays, particularly for upcoming product approvals, could affect timelines.
• Economic uncertainties may influence healthcare spending and investment.

Q&A

During the earnings call, analysts inquired about the impact of new HAE competitors, with management expressing confidence in maintaining market leadership. Questions also focused on the company’s pipeline opportunities in Netherton Syndrome and diabetic macular edema (DME), with BioCryst highlighting its strategic investments in these areas.

Full transcript - BioCryst Pharmaceuticals Inc (BCRX) Q2 2025:

Conference Operator: Good day, and welcome to the BioCryst Second Quarter twenty twenty five Earnings Conference Call. All participants will be in the listen only mode. After today’s presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your telephone keypad. To withdraw your question, you may press star, then 2.

Please note this event is being recorded. Would now like to turn the conference over to John Bluth. Please go ahead.

John Bluth, Investor Relations, BioCryst: Thank you very much. Good morning, and welcome to BioCryst’s second quarter twenty twenty five corporate update and financial results Call. Today’s press release and accompanying slides are available on our website. Participating with me today are CEO, John Stonehouse President and Chief Commercial Officer, Charlie Guyer Chief R and D Officer, Doctor. Helen Thackray Chief Medical Officer, Doctor.

Donald Fong and our new Chief Financial Officer, Bob Urgeas. Following our remarks, we will answer your questions. Today’s conference call will contain forward looking statements, including those statements regarding future results, unaudited and forward looking financial information as well as the company’s future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward looking statements.

For additional information, including a detailed discussion of our risk factors, please refer to the company’s documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today’s conference call includes non GAAP financial measures. For a reconciliation of these non GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the Press Releases section of our Investor Relations website at www.biocryst.com. I’d now like to turn the call over to John Stonehouse.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Thanks, John. Q2 was another outstanding quarter of performance for BioCryst. For Orlodayo, it was the best quarter since approval, both from a revenue and underlying new patient demand perspective. To be in the fifth year of the launch and growing so sustainably quarter after quarter is a result of great execution by the team and continued growing confidence in the product. The commercial team at BioCryst has learned so much in the marketplace and made adjustments along the way that has kept this growth sustainable.

Our recipe for success has been combining talented, motivated people, data and insights to very acutely understand the market and our customers, and focused execution. We show up differently than our competition. I know this as I saw it recently at the USHAE Patient Summit, a gathering of over 1,000 patients and their families and many leading KOLs. They shared with me and other members of our team the growing confidence they have in our product. Many made the effort to seek us out and describe how Orlodayo has changed their lives.

This underscores when the product works for a patient, it works very well, and the number of patients experiencing both efficacy and convenience continues to grow steadily. There is little doubt that we are on a path to $1,000,000,000 at peak and market leadership with Orlodeaux. But to create even greater value, we need to do it again with another product. It is clear that we must source our pipeline through both internal research and BD. Our Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year.

We also signed a definitive agreement to sell our European business to Neo Pharma Gentile or NG and we are working hard to complete all the necessary steps to close the deal in early October. This deal puts us in such a strong financial position enabling us to pay off our term debt while generating an increasing operating profit margin. We believe it puts us on a path to generate more and more cash flow and that we will remain on this path through the rest of the decade and beyond. Pipeline progress and financial flexibility enable us to continue to advance our pipeline while looking for assets from other rare disease companies. We have built an outstanding commercial capability at BioCryst, we plan to leverage it over time by bringing multiple products to the market to create greater and greater value.

Before I turn the call over to Charlie, want to say how excited I am to see the company move to the next stage of growth, call it BioCryst two point zero. Charlie has built one of the most successful rare disease commercial engines ever, and now we are able to leverage this engine to become the consolidator of rare disease assets. We have built a great reputation through a track record of success, and now we have the financial strength to execute this strategy. So it’s time to change the leadership to execute the strategy and take the company to the next phase. After an extensive succession planning process assessing both internal and external candidates, it’s great to have our board unanimously choose Charlie as our next CEO.

I’ve seen Charlie grow as a leader for almost a decade now, and he has earned the job as the next CEO and he is ready to lead the company. I look forward to working with Charlie and the team in these remaining months to make this a smooth transition into the new year. With that, I will turn it over to Charlie.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Thank you, John. It’s an incredible honor to be chosen to lead this company, and it is not lost on me that I would not be in this position nor would ViaCryst have reached this exciting point without your leadership. And thanks to all our colleagues who work so hard every day to bring transformative therapies like Orlodea to patients. You are making a big difference and we are just getting started. And what a start it has been for ORLIDEA.

We are halfway through year five since launch and ORLIDEA continues to build momentum that is reaching a new level. The second quarter was the best ever for The U. S. With new patient prescriptions up over 10% above the first quarter of the launch in 2021 and over 15% above Q1 this year. ORLIDEAL revenue greatly exceeded our expectations, over $22,000,000 above Q1 and 45% growth year over year, and it did so for several reasons.

The spike in new patient demand, further efficiency in getting paid shipments, lower discontinuations during the 2025 compared to last year, gross to net improvements, and strong international results all contributed in roughly equal parts to generate the overperformance. Each of these factors was a direct result of our team’s continued focus on execution. With this strong second quarter, we are confident that we will reach the upper half of our revenue guidance of $580,000,000 to $600,000,000 for the full year even after removing fourth quarter European revenue after closing the sale of our European business, which we anticipate in early October. We expect to provide more detailed guidance on the go forward BIACRIST business at our third quarter earnings call in November. The spike in demand was only one component of the surge in revenue in Q2, but the prescription trend bodes particularly well for long term growth.

We saw an uptick in new U. S. Prescribers with 69 compared to 59 in Q1, and existing prescribers continue to prescribe Orlodayo to more of their patients. A big factor in the jump is the confidence physicians gain when they see our large volume of real world evidence. For example, we recently released data showing that a large cohort of HAE patients with normal C1 inhibitor experienced substantial reduction in attack rates after starting Orlodea.

This analysis of over three fifty patients tracked for up to eighteen months is helping physicians offer new hope for a segment of the HAE community that has struggled to get effective care for years. There was a lot of excitement at the recent HAE Summit because diagnosis and treatment of HAE with normal C1 inhibitor was a major part of the agenda as presenters described new consensus guidelines that were created in partnership with the patient community. U. S. Payers reimburse Orlodeyo for normal C1 at a rate about ten percent less than for type I and II patients, but our evidence generation and the expert consensus statements are helping to close that gap.

Strong and consistent demand from Type I and II patients, the increasing demand from patients with normal C1 inhibitor, and the future pediatric demand from the anticipated FDA approval of Orlodeyo granules in December set us up to continue revenue growth momentum into 2026 and beyond. I’ll turn

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: it back to John in his role as acting CFO for the second quarter to review the financials. Thank you, Charlie. To make such positive and significant strides commercially while advancing our pipeline during the quarter is great to see. To be able to achieve all of that while continuing to improve our already strong financial position makes it even better. So let me walk you through the financials.

While you can find the detailed second quarter financials in today’s press release, I’d like to draw your attention to a few items. Total revenue for the quarter came in at $163,400,000 $156,800,000 of which came from Orlodayo. Of that Orlodayo revenue, 140,300,000.0 or almost 90% was generated in The U. S. For Orlodayo revenue, that represents 45% growth in quarterly revenue over the same quarter last year.

Non GAAP operating expenses, excluding stock based comp and deal related costs, were $106,400,000 for the 2025, up from $87,400,000 in 2024. Based on the investments we’ve made in the past, we have started to see strong operating leverage in our business. As you would expect, some of this increase was driven by continued investment in our R and D programs and details on expense drivers can be found in our press release. Non GAAP operating profit for the quarter, excluding stock comp and deal related costs, was $57,000,000 and our non GAAP net income for the quarter was $32,300,000 resulting in a non GAAP EPS of $0.15 We generated $45,000,000 of cash in the second quarter before any debt prepayment. Based on the continued strength in our cash position, we paid down $75,000,000 in principal from our term loan in April and an additional 50,000,000 in July.

This reduces the balance of our term debt to $199,000,000 and our intent is to pay it off in full upon closing the sale of the European business in early October. The cumulative effect of these prepayments enables approximately $90,000,000 of net interest savings over the life of the loan. Our accelerating cash flow generation enables us to reach an expected $700,000,000 in cash by 2027. However, we don’t plan to sit on the cash, but to actively deploy it into value creating opportunities. This strong financial performance alone represents great progress for the company, but to pair it with a commercial team firing on all cylinders and the great progress that we have made advancing our pipeline, it’s even more remarkable.

This was a great quarter to conclude my brief stint as acting CFO, and I’m delighted to welcome Bobber Gias to the team as our new CFO. Bobber’s extensive deal making and operational experience in addition to his previous roles as CFO at rare disease companies are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and increasing value. I’ve been impressed with how quickly he’s gotten up to speed and integrated with the team. The growing financial strength of the business and the inorganic opportunities available present present exciting prospects for BioCryst two point zero. With that, I will turn it over to Bobber.

Bob Urgeas, Chief Financial Officer, BioCryst: Thank you, John. To have achieved such a strong quarter and great progress in the last few months during your tenure as interim CFO is a testament to the amazing finance team that we have here at BioCryst. Their positive attitude and desire to make this company better have been evident to me immediately, and I’m excited to work with them. I’m honored to be joining the Biocryst team at such a pivotal point for the company. The continued strength of Oladeo and the recently announced European business sale creates several value enhancing options for BioCryst.

It enables us to streamline our operating structure upon completion, improving our overall profit margins. Our plan to pay down our outstanding debt will further boost earnings from future interest expense savings. And most importantly, our strong cash flow profile combined with an unlevered balance sheet going forward provides us the ability to deploy capital in building sustainable shareholder value, whether it’s in licensing pipeline programs, product or company acquisitions, or even return of capital to shareholders in the future. This next journey of BioCryst is going to be a very exciting one, and it’s great to be here. Operator, we’ll now open the call for Q and A.

Conference Operator: Certainly. We will now begin the question and answer session. Our first question comes from Jessica Fye with JPMorgan. Please go ahead.

Abdul, Analyst, JPMorgan: Hi. This is Abdul on for Jess. Congrats, John, on your upcoming retirement and Charlie and Barbara on the new roles. I just have two quick questions. So first, of the 45% year over year Orlodea net rev growth, how much of that was volume, and how much was better paid rate or net price?

And then you mentioned an improved discontinuation rate for first half twenty twenty five and first half twenty twenty four. What are the numbers you’re seeing there and what do you think is driving that? And should we expect the trend to continue and why? Thanks.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Yes.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: For the growth in Q2, as I said in my prepared comments, it was a mix of everything from volume. There was some growth to net improvement. We were also just more efficient in squeezing out more paid shipments during the quarter. So it was a big mix of everything. But what I’m really excited about is the fact that the demand was so high because that’s what’s going to drive the long term growth and it was better than ever.

And sorry, the second part of the question, can you repeat that part?

Abdul, Analyst, JPMorgan: The second question or the second part of the first question?

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Sorry, the second question.

Abdul, Analyst, JPMorgan: Yeah, so you mentioned an improved discontinuation rate for the ’25?

John, Analyst, Citizens: Yeah.

Abdul, Analyst, JPMorgan: What numbers are driving that there? Do we expect to continue that?

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: What we’ve seen over the last several years, and it’s true in the first half of this year as well, is that the one year discontinuation rate has been rock solid. Sixty percent of patients who start make it to a year, that really hasn’t shifted. Where I think we’ve seen a little bit of an improvement as our patient base grows, the overall discontinuation rate is trending slightly down because patients who make it to a year, they’re doing really well, they stay on therapy. And so it’s exactly what you wanna see and I would expect to see this kind of same solid discontinuation or retention rate going forward.

: Thank you.

Conference Operator: Thank you. Our next question comes from Laura Chico with Wedbush Securities. Please go ahead.

Laura Chico, Analyst, Wedbush Securities: Good morning. Thank you very much for taking the question. My congrats to John, Charlie, Bobar. Thank you. So I guess I had just one your comments on discontinuation rates made us a little curious here.

Could you speak a little bit to persistency rates in relationship to other injectable prophylactic regimens? And I realize there’s probably no direct head to head studies, but wondering if you can comment here on any real world data just that puts into context the persistency you’re now seeing with Orlodayo versus the injectable products? Thank you.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Yeah, thanks Laura. We actually put out some data at a recent conference. I think it was, last fall at the college meeting. We looked at healthcare claims data for both Orlodeyo, for TAXIRO and HAYGARDA, and looked at patients starting any of those three products and looked at the one year persistence rate. The one year rate is statistically identical for all of them, around sixty percent.

Numerically, actually, Orlodea was a little bit better than the other two. And so I think what that shows to us is no single HAE therapy is perfect for every patient. We know that about seventy percent of patients would prefer to treat with an oral prophy product. It shows that Orlodayo has got the profile that patients want and performs really well in the real world.

Laura Chico, Analyst, Wedbush Securities: Thanks very much.

Conference Operator: Our next question comes from Steve Seedhouse with Cantor. Please go ahead.

John, Analyst, Citizens: Good morning. Thank you. Congratulations, John, Charlie, Bob, really everyone on the quarter as well. Two questions. First, any early indications of how the June and July approvals in HAE, so geradasumab and Ecterly are affecting or Ladeo demand over the past month?

And also any additional color you can provide on the pediatric PDUFA delay just to give us comfort there? Thank you.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Sure. On the new approvals, just had by a substantial margin, the most new patient prescriptions ever. So what it shows is physicians aren’t waiting for any of these new products, which is exactly what our long term market research has shown. Orlodea was the most differentiated prophy in the market and I expect our demand to continue. Yeah, I think it’s important to remember

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: that we’ve told you patients don’t see their doctor much more than once or twice a year. So if they were going to have that conversation, they would have it set up and we’re not seeing that. So, I think that’s at least an early good sign for us. You want to take the pediatric?

Helen Thackray, Chief Medical Officer, BioCryst: Yeah, and the question on pediatric the PDUFA date. So the FDA, upon receiving some final reports and some responses that we gave them, decided that they needed a little more time to review. So that’s a major amendment to the NDA and that leads us to PDUFA date of December 12. So, we’re on track for that.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Yeah, and we knew when we submitted the original filing that we had these reports that we had to get in. If we had waited for those, we would have virtually the same PDUFA date. So, we thought we would take a shot at that. We’re excited. The key is we’re going get approval this year, and we’re excited about that.

John, Analyst, Citizens: Thanks so much. Yes.

Conference Operator: Our next question is from Tazeen Ahmad with Bank of America. Please go ahead.

John Bluth, Investor Relations, BioCryst0: Hi. Good morning. Congrats on a great quarter once again. I just wanted to maybe get a little bit of color on what you think your penetration rate is into the addressable market today. And, where are you seeing most of your use?

Is it more from doctors who’ve tried Rolodayo, like the results, and keep prescribing it, or are you seeing an acceleration of new doctors coming on board to write scripts for the first time? Thanks.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Hey, Charlie. You might wanna talk too about pace, cause I think that’s an important piece that people might not understand.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: To Zane, from penetration rate perspective, we’ve noted before at the 2024, about three thousand patients had already tried BorlaDay, roughly half of those are still on therapy. Recall that we’ve also put out data that there are about 11,000 diagnosed patients in the market. We still have a lot of upside growth remaining. As far as healthcare providers, I was really thrilled that we had 69 new prescribers in Q2 this late in the launch. It shows that we keep finding convincing more doctors.

The overall split of prescriptions tends to still be about fiftyfifty with about half of them being from Tier one physicians, the top 600 roughly that treat half the patients in the market. And then the other half comes from the wider base of other physicians who have just a few patients. What seeing overall, and John mentioned this in his comments, I alluded to this as well, there’s just more confidence amongst physicians in the long term data that they’re seeing the data that we present to them and then also what they experience themselves. So they’re really thinking about Orlodea very differently than they were a few years ago. And they have confidence in switching patients, which is still roughly fifty percent of the patients.

They’re confident in putting acute only patients, having them come over to prophy start with Orlodeyo. And then patients naive to therapy as well. When they start on a prophy, Orlodeyo is the natural place. So we’re capturing all the segments. Charlie spent a bit of

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: time in his prepared remarks talking about normal C1 patients, and that is a real opportunity for us, a place that historically physicians have not had great success in either diagnosing or treating. We’ve generated meaningful data, three fifty patients worth of real world evidence showing pretty amazing reductions in baseline attack rates on Orlodea with these patients. So those are examples of areas that the team just keeps scouring and finding. That’s why you keep seeing this sustainable growth.

John Bluth, Investor Relations, BioCryst0: Thanks for the color, guys. And then just maybe to follow-up. Are you expecting that stickiness topic that has come up on several calls to continue as you add new patients? How reliable do you think they’ll be to stay on therapy if new potential new oral competitors come online? Thanks.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Sure. No, I think extremely sticky. You either do great on Orlodea and you stay on, or you don’t, you move off. So I don’t think patients are not waiting for some hypothetical future oral product. They’ll switch today.

They’ve got a lot of good injectable options. If they don’t get what they need from Orlodeaux, they’ll switch. So I think the patients that stay are very sticky.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Yeah, and the last thing I’d say is what would be better than a once a day highly effective drug, right? Like what behind us is coming that is better? There really isn’t a profile that’s better, so we expect it to be very sticky, as Charlie said.

John Bluth, Investor Relations, BioCryst1: Okay.

Conference Operator: Thank you. Our next question is from Gena Wang with Barclays. Please go ahead.

John Bluth, Investor Relations, BioCryst2: Thank you for taking my questions. Also, on the strong quarter. So maybe, Charlie and the team, if you can give a little bit more color regarding the launch metrics in 2Q regarding the reimbursement product rate, I think the last quarter was at 84% and retention rate just want to confirm, is that consistent stay at a 60%? And then if you can provide any other metrics regarding the patient segment? And then second question is regarding the timing for the two pipeline assets.

I know you said that by the end of by year end ’25 for two pipeline assets, maybe any additional color you can share regarding the patient enrollment and expectation for the data? Lastly, very quickly, just wanted to ask, John, I know it has been a great working with you. Then just wondering, what’s the reason regarding the timing for transition to the next journey of your life?

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Great. Charlie, you wanna take the

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: first one? Sure, Gina. As far as the launch metrics, I mentioned in my prepared remarks we were able to part of the over performance in the quarter is we got more paid shipments out of our patient population than we have historically on a trend rate. So that was part of the overperformance. The actual paid rate is doing exactly what I predicted last quarter, which is we reach a high watermark around the April timeframe when we come off of the reimbursement sorry, the reauthorization season.

And then for the rest of the year, the paid rate tends to be dominated by new patients coming in. What that means is it drifts down slightly over the course of the year, by a we would expect it to go a percentage or two down by the end of the year, and we’re on that trend. So we feel really good about where we are. Then next year, we’ll recover that and probably take the reimbursement rate to a new high. As far as retention, as I mentioned in the last question, it’s been really solid.

That one year 60% retention rate, has been consistent for the last roughly three years. And it’s because patients, as I said, they either do really well, and they stay on, or they move on to a different product.

Helen Thackray, Chief Medical Officer, BioCryst: And then with regard to the pipeline question, we have two programs in the pipeline, both in the clinic that we’re progressing with data anticipated by the end of the year. They’re both progressing well on track for Nederton syndrome. Our program is 17,725, for which data this year will be both on exposure, the penetration of the drug in the skin, and on potential efficacy endpoints, including itching and healing of the skin. So we anticipate having initial data for that drug for those endpoints by the end of the year. For Vorlestat, this is a trial in patients where one dose will give sustained exposure.

We expect to have exposure over months and so what we’re looking for is how patients do once they’ve had that single dose. This is treating for DME, so we’ll be looking for effect on the retina and the potential for reducing the swelling in the retina. And as I said, it gets exposure over months, but we’ll be looking at four weeks, eight weeks, twelve weeks in. So that initial data will be coming this year too.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Great. And then in terms of timing for me, Gina, thank you by the way, it’s been great working with you as well. It’s time. I don’t know how else to say it. I turned 65 this year.

I’ve been in the company. It’ll be nearly nineteen years when I leave. The company is in great shape. The board and I have been working on this succession for over a couple years, and Charlie’s a great choice. So it all just kind of lined up, and it’s just perfect timing.

So that’s my answer.

Conference Operator: Thank you. Our next question is from the line of Stacy Ku with TD Cowen. Please go ahead.

John Bluth, Investor Relations, BioCryst3: Hey, good morning. A quick congratulations to both John and Charlie on the announcements. You both have done amazing things together with the BioCryst team. So a few questions. One quick follow-up.

Just longer term, maybe remind us how you’re thinking about the on demand launch of oral Actorly as we think about as you always had thought, that would be a benefit for you all. So just help us understand, is the sales force able to maybe regrab share with patients that had to go back on injectables with Orlodea? Is that low hanging fruit? And then from a payer perspective, how are they going to handle all this? So just maybe some more details there as we’ve been getting some investor questions.

And then second, a little bit of a just double checking here. As we think about the paid shipments in Q2, just want to understand, is there any implications on a quarterly basis, something that has come up with other companies? So just want to make sure there’s no changes to the normal quarterly cadence. And then last, we see the IND approval by the FDA for Nathetern, so congratulations there. As we await data, remind us the current competitive landscape there and what kind of learnings you all are taking.

Thanks so much.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Sure. Thanks, Stacy. As far as the role of Ectorly, yeah, we think patients are really excited. The ability to ultimately have an all oral combination where you take an oral prophy and then when you have an occasional breakthrough attack, be able to treat it with an oral as well. It just adds to the convenience and for patients just being able to worry less and kind of forget that they have HAE.

We saw that excitement at the HAE Summit, last month. And so we do think there’s a potential positive upside, both in terms of attracting patients to Orlodayo and for patient retention if they’re also taking or using an oral on demand. What we definitely know from speaking to patients and physicians in large numbers is prophy is still the backbone of therapy that they’re looking for and in particular oral prophy. As far as paid ships in Q2, nothing that we’re seeing out of the ordinary. The improvements that we’re seeing is just about our team’s execution.

And then I would expect for the rest of the year, a similar quarterly cadence to what we saw last year, where the revenue growth slows down a bit relative to Q2 because we’re out of the reauthorization season. And so I would expect it to look quite similar with Q3 and Q4 growing according to our new patient demand. And then with regard to the competitive landscape,

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: I mean, it’s always hard to say stuff with any certainty, but Daiichi, we haven’t heard boo from their program in almost two years, and so that’s probably not a good sign. And we’ve heard that for business reasons that they’ve terminated. We don’t know if that’s true or not, because we’ve heard that. And then BI had a program that I think they out licensed or sold to a company. Usually you don’t sell an asset if you have a lot of value and confidence in an asset.

So that probably doesn’t bode well. So we could be the first therapy, which would be amazing because I think we were third or fourth even when we were first looking at this. This is a place where the unmet need is huge. So we’re really excited about it and eager to get the data to have a sense of dose and is it getting to the skin and is it having an effect? Stay tuned.

John Bluth, Investor Relations, BioCryst1: Thank you so much.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: You’re welcome.

Conference Operator: Our next question comes from Brian Abrahams with RBC Capital Markets. Please go ahead.

John Bluth, Investor Relations, BioCryst4: Hey, guys. Thanks for taking my questions. John, congrats on all your career achievements and congratulations as well to Charlie and Babur on your new and upcoming roles. Two bigger picture questions for me. I guess, first, for most favored nation policy, how do you guys model that playing out and potentially affecting you guys, if at all, particularly with European pricing that’s no longer going to be under your control?

Maybe remind us of your overall Medicaid exposure. And then secondly, you talked a lot earlier in the call on deployment of capital. And I guess I’m curious how you’re viewing the market for buyers here, how competitive it is, the types of opportunities that you might be interested in, in terms of stage and segment and your optimal timelines Thanks.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Sure. So Charlie, you want to take the first one, Bob So will take the

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Brian, as far as MFN, obviously like others, we’re watching this, but I think we’ve seen anything specific that would apply to us. And so we’ll just keep executing and watching that space. Medicaid for us is a relatively small segment. It actually is sort of between 1015% of our patients. So we’ll just watch, but right now, we don’t see an immediate impact.

Bob Urgeas, Chief Financial Officer, BioCryst: And Brian, your next question, the market couldn’t be better for if you’re a buyer at the moment, and you don’t need to tap or raise more capital. And I think that’s what we you heard from the remarks that we are in an enviable position of having sustainable cash flow. But let me give you a little bit more color. We will be broadly looking at the rare disease space. We want to be a consolidator of rare disease assets.

So assets where we can where there’s high unmet needs and we can leverage our operational infrastructure. We have a very promising early pipeline, so we will look to balance our portfolio with more later stage assets, post proof of concept, soon to be commercial and or even commercial assets. So, think the next couple of months will be very interesting from that vantage point, and we’ll have some more developments over the next coming months.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Yeah, and Brian, you know, firsthand that companies are really struggling to find capital to fund their operations, whether it’s clinical development or launching a product. It’s just a tough spot for people to be in and an opportunity for us.

John Bluth, Investor Relations, BioCryst4: Congrats on the strong quarter that puts you in that position, and thanks again for taking our

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Yes. Thanks, Brian.

Conference Operator: Our next question comes from John Wallabin with Citizens. Please go ahead.

John, Analyst, Citizens: Hey, thanks for taking the question and sharing our congrats to John and Charlie as well.

John Bluth, Investor Relations, BioCryst4: I was hoping you

John, Analyst, Citizens: guys could talk a little bit about typical second half push and pulls with like about $290,000,000 in first half revenue. No, not much has to go right for you guys to hit that lower end of your guidance. So wondering if you think kind of all the positive dynamics here in 2Q are going to continue or just a little bit about what you see typically second half and what you’re seeing so far this year? Thanks.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Sure, John. Second half, as I’ve said, tends to be, it’s driven by new patients coming in and it takes a little bit longer to get a new patient or the new patient population to the same paid rate, as our overall population. And so therefore, number one, the overall paid rate tends to go down, it’ll probably go down a percentage point or two in the second half. We don’t have the opportunity to bring a big bolus of patients from new prescriptions or from long term free product over to paid the way that we do in the first quarter into early the second quarter. And so we expect those same dynamics second part of this year and all signs show that our demand is going to continue to be really strong.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: And the last thing that I’d say in terms of the dynamics is remember that the fourth quarter, we will not have European revenue. And we’ve guided you to what that trailing twelve months was in terms of the revenue that was being generated when we announced the deal. You can add a little bit extra for the fourth quarter because it’s usually a little bit higher. But that’ll give you some sense of what to deduct out of the fourth quarter Yes.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: And John, you may have heard me say, but I did say in my comments, I expect us to be in the upper half of our $580,000,000 to $600,000,000 but after subtracting European revenues in Q4.

John, Analyst, Citizens: Got it. Okay. Thanks, guys. That’s helpful. Welcome.

Conference Operator: The next question comes from Serge Belanger with Needham and Company. Please go ahead.

John Bluth, Investor Relations, BioCryst5: Hi, good morning and congrats on another strong quarter. Charlie, you mentioned a couple of factors behind the strength of Orlodo this quarter. You did mention an improvement in gross to net. So just curious if it’s still within that prior 15% to 20% range. And you also mentioned you hit a new high watermark in new patient adds.

How does that compare to 2024 levels when I believe you add about 300 patients for the year? And then lastly, just given the overall expansion of the prescriber base and the strong patient add, is there a case here to add on to the current sales force to take advantage of this strength? Thanks.

Charlie Guyer, President and Chief Commercial Officer, Incoming CEO, BioCryst: Sure, thanks Serge. As far as gross to net, yeah, we’ve been really efficient this year. And some of that is just the mix with Medicare patients getting up to a higher paid rate as we talked about last quarter, and there’s a bunch of other factors as the team manages it. So I think we’re in the lower portion. We’re still in the 15% to 20%, but closer to 15% off of net price.

And then as far as new patient adds compared to 2024, at the end of Q1, I did mention Q1 was a really good quarter this year and last year was the best year we had since the first year of launch. Q1 was just a little bit better than the best quarter of last year. And then Q2 this year blew away Q1. So we’re doing really well on the new patient adds. And then as far as the prescriber base, and do we need more reps?

No, we don’t. We have a fantastic team out there. They are able to cover the population. They’re able to expand the number of prescribers quarter after quarter. And actually, if we added more people, it would decrease our efficiency and probably just tick off our customers.

So we’re not gonna do that. And one thing that’s been great is we’ve been growing our revenue, but our actual direct commercial spends are hardly going up at all. And that’s because we’ve got the right data, the right message, the right team, and they’re executing in a phenomenal way.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: And kind of back to what Barbara was saying about leveraging the existing infrastructure that we have. We have made investments in patient services and more data to be smarter about where we might find more physicians. But that we can use for any product in the future. And it’s not direct salespeople that you have to add. So that’s why we were so convinced that putting more products into this well oiled commercial machine is going to create greater and greater value.

John Bluth, Investor Relations, BioCryst5: Thank you.

Conference Operator: Our next question comes from Maury Raycroft with Jefferies. Please go ahead.

John Bluth, Investor Relations, BioCryst1: Hi. This is Amy on for Maury. Thank you for taking our questions and congrats on the quarter. We have two questions on the pipeline programs, Nederton and DME. For the Nederton, what is your latest thoughts on the pivotal trial design and regulatory timeline for this indication?

Is there a defined pathway for accelerated approval either from precedence or clear KOL or FDA feedback? And for the DME program, like what would the outcomes from the Phase three study contribute to the design of phase two or even the pivotal? And for the retinal, swelling reduction results that we are expecting to see at the end of this year, what is the bar that, we need to beat here? Thank you.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Helen, you want to take the first one, Don take the second one?

Helen Thackray, Chief Medical Officer, BioCryst: Yeah, Nederjen syndrome. The pivotal trial, so this is a really interesting program because it is one in which there is an unmet need and it’s a very serious disease, which means you don’t need to see much effect and you don’t need to see it in many patients to demonstrate that the drug is going to be beneficial for patients. What we expect is seventeen seventy five is a very large effect. It’s a potent drug with high affinity. It’s a targeted drug and it’s intended to essentially provide a replacement of the missing enzyme function.

So, pivotal trial design will be looking at what is the effect that matters to patients? What is the effect on an improvable endpoint? And we think that is changes in the skin, both how it’s healing, so assessment of the skin, the patient’s experience, the itching. Those are relatively simple to measure. We’ll be looking at those in our current trial.

We’ll be looking at those in a pivotal trial. It’s possible this could be a very short path to pivotal. It’s possible also it could be then a short path to a registration endpoint and submission to the FDA. What that looks like and when it is, we can’t say at this point. We need to talk with FDA and get their input.

We need to understand if they agree with us on the endpoints in the past. But we do think that this is

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: a program that could warrant a smaller dataset and a relatively simpler path to registration. I think too, the fact that competition question that came up earlier, if we’re first, we may be able to go really fast depending on what kind of treatment effect we have, so we’ll see. And then Don, let me set up the DME and then you can hit the specifics. So just to remind you, what we’re trying to do is get a sense of do we have activity and do we have some sense of dose? And does kallikrein, plasma kallikrein play a role in DME as an alternative pathway to VEGF?

Those are all questions we’re hoping to answer. With a small investment in a phase one study with a single dose in a handful of patients roughly. From there, we would make the next investment, which would be a proof of concept study and then ultimately to get approval. But if we’re able to prove that Celekron plays an alternative role and we have a drug that actually affects that, it’s off to the races for us. But I’ll let Don describe what we hope to see towards the end of this year.

: Yeah, thank you, John. I think that is correct. The Calcryne pathway is an independent pathway of the VEGF pathway. We just presented some preclinical evidence at the American Society of Retina Surgeons this last weekend, and there was a lot of excitement about a new pathway for our product. In answer to your specific question of what the pivotal study would look like, the path for approval of, drugs for DME is best corrected visual acuity.

So we will be looking for a similarity or non inferiority to existing anti VEGF products. In our Phase II design, we will be looking specifically at change in central subfield thickness. That will give us indication that Avarostat product is effective at reducing central subfield thickness and macular edema.

John Bluth, Investor Relations, BioCryst1: Thank you. That’s very helpful.

Bob Urgeas, Chief Financial Officer, BioCryst: You’re welcome.

Conference Operator: Thank you. We have no further questions at this time. I would now like to turn the conference back over to John Stonehouse for any closing remarks.

John Stonehouse, CEO (Outgoing), Acting CFO, BioCryst: Yeah, don’t think there’s a whole lot more to say when you have a quarter like we did, where you have growing revenue, profit, great cash flow, the start of great cash flow and strong underlying demand continuing to increase, it doesn’t get any better than that. And we’re going to continue to execute and looking forward to how the rest of the year unfolds. So thank you for your interest. Have a great day.

Conference Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.